GB0106661D0 - Pharmaceutically active compounds - Google Patents

Pharmaceutically active compounds

Info

Publication number
GB0106661D0
GB0106661D0 GBGB0106661.2A GB0106661A GB0106661D0 GB 0106661 D0 GB0106661 D0 GB 0106661D0 GB 0106661 A GB0106661 A GB 0106661A GB 0106661 D0 GB0106661 D0 GB 0106661D0
Authority
GB
United Kingdom
Prior art keywords
active compounds
pharmaceutically active
curative
inhibition
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0106661.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Pfizer Inc
Original Assignee
Pfizer Ltd Great Britain
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd Great Britain, Pfizer Inc filed Critical Pfizer Ltd Great Britain
Priority to GBGB0106661.2A priority Critical patent/GB0106661D0/en
Publication of GB0106661D0 publication Critical patent/GB0106661D0/en
Priority to MXPA03005937A priority patent/MXPA03005937A/es
Priority to ES02701497T priority patent/ES2231667T3/es
Priority to JP2002573783A priority patent/JP2004523585A/ja
Priority to BR0208154-7A priority patent/BR0208154A/pt
Priority to CA002439528A priority patent/CA2439528A1/en
Priority to PCT/IB2002/000659 priority patent/WO2002074774A1/en
Priority to EP02701497A priority patent/EP1368352B1/en
Priority to AT02701497T priority patent/ATE283856T1/de
Priority to DE60202134T priority patent/DE60202134T2/de
Priority to US10/096,190 priority patent/US6770645B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GBGB0106661.2A 2001-03-16 2001-03-16 Pharmaceutically active compounds Ceased GB0106661D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GBGB0106661.2A GB0106661D0 (en) 2001-03-16 2001-03-16 Pharmaceutically active compounds
DE60202134T DE60202134T2 (de) 2001-03-16 2002-03-04 Zyklische guanosine 3',5'-monophosphate phosphodiesterase inhibitoren
BR0208154-7A BR0208154A (pt) 2001-03-16 2002-03-04 Inibidores de fosfodiesterase 3',5'-mono-fosfato guanosina cìclica
ES02701497T ES2231667T3 (es) 2001-03-16 2002-03-04 Inhibidores de la 3',5'-monofosfato de guanosina ciclico fosfodiesterasa.
JP2002573783A JP2004523585A (ja) 2001-03-16 2002-03-04 サイクリックグアノシン３’，５’−モノホスフェートホスホジエステラーゼ阻害剤
MXPA03005937A MXPA03005937A (es) 2001-03-16 2002-03-04 Compuestos farmaceuticamente activos.
CA002439528A CA2439528A1 (en) 2001-03-16 2002-03-04 Cyclic guanosine 3',5'-monophosphate phosphodiesterase inhibitors
PCT/IB2002/000659 WO2002074774A1 (en) 2001-03-16 2002-03-04 Cyclic guanosine 3',5'-monophosphate phosphodiesterase inhibitors
EP02701497A EP1368352B1 (en) 2001-03-16 2002-03-04 Cyclic guanosine 3',5'-monophosphate phosphodiesterase inhibitors
AT02701497T ATE283856T1 (de) 2001-03-16 2002-03-04 Zyklische guanosine 3',5'-monophosphate phosphodiesterase inhibitoren
US10/096,190 US6770645B2 (en) 2001-03-16 2002-03-12 Pharmaceutically active compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0106661.2A GB0106661D0 (en) 2001-03-16 2001-03-16 Pharmaceutically active compounds

Publications (1)

Publication Number Publication Date
GB0106661D0 true GB0106661D0 (en) 2001-05-09

Family

ID=9910932

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0106661.2A Ceased GB0106661D0 (en) 2001-03-16 2001-03-16 Pharmaceutically active compounds

Country Status (10)

Country Link
EP (1) EP1368352B1 (https=)
JP (1) JP2004523585A (https=)
AT (1) ATE283856T1 (https=)
BR (1) BR0208154A (https=)
CA (1) CA2439528A1 (https=)
DE (1) DE60202134T2 (https=)
ES (1) ES2231667T3 (https=)
GB (1) GB0106661D0 (https=)
MX (1) MXPA03005937A (https=)
WO (1) WO2002074774A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE478872T1 (de) * 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
WO2004054560A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
CN100374441C (zh) * 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
PL2256106T3 (pl) 2003-07-22 2015-08-31 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
WO2005028480A2 (en) * 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
US7485637B2 (en) 2005-01-04 2009-02-03 Hoffmann-La Roche Inc. Benzoyl-tetrahydropiperidine derivatives
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
DE602006010665D1 (en) 2005-02-07 2010-01-07 Hoffmann La Roche Heterocyclsche substituierte phenylmethanone als inhibitoren des glycintransporters 1
CA2598271A1 (en) * 2005-02-18 2006-08-24 Surface Logix, Inc. Pharmacokinetically improved compounds
US8017781B2 (en) 2005-11-15 2011-09-13 Vertex Pharmaceuticals Incorporated Azaindazoles useful as inhibitors of kinases
CA2629077C (en) * 2005-11-16 2014-03-18 F. Hoffmann-La Roche Ag Novel process for the preparation of thoc
US8071765B2 (en) * 2006-12-21 2011-12-06 Topharman Shanghai Co., Ltd. Process for the preparation of sildenafil and intermediates thereof
RU2470635C2 (ru) * 2007-05-11 2012-12-27 Сантен Фармасьютикал Ко., Лтд. Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза
JP5498392B2 (ja) 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
JP5453431B2 (ja) 2008-09-08 2014-03-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピラゾロピリミジン及びｃｎｓ障害の治療のためのそれらの使用
EP2379076B1 (en) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
PE20120505A1 (es) 2009-03-31 2012-05-09 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
TWI393578B (zh) 2009-07-07 2013-04-21 Shl Group Ab 注射裝置
AP2012006631A0 (en) 2010-08-12 2012-12-31 Boehringer Ingelheim Int 6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
EP2699572B1 (en) 2011-04-21 2016-08-10 Origenis GmbH Heterocyclic compounds as kinase inhibitors
MX363696B (es) 2011-04-21 2019-03-28 Origenis Gmbh Pirazolo[4,3-d]pirimidinas utiles como inhibidores de cinasas.
KR20140138293A (ko) 2012-03-16 2014-12-03 액시킨 파마수티컬스 인코포레이티드 3,5-다이아미노피라졸 키나아제 억제제
WO2014060112A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
US10000482B2 (en) 2012-10-19 2018-06-19 Origenis Gmbh Kinase inhibitors
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015091428A1 (en) * 2013-12-20 2015-06-25 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
US9546163B2 (en) 2014-12-23 2017-01-17 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
PL3377495T3 (pl) 2015-11-16 2022-05-16 Topadur Pharma Ag Pochodne 2-fenylo-3,4-dihydropirolo[2,1-f] [1,2,4]triazynonu jako inhibitory fosfodiesterazy i ich zastosowania
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
UY40234A (es) 2022-04-22 2023-11-15 Vertex Pharma Compuestos heteroarilo para el tratamiento del dolor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1493685A (en) * 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
US6225315B1 (en) * 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
AP2002002455A0 (en) * 1999-10-11 2002-06-30 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.

Also Published As

Publication number Publication date
DE60202134T2 (de) 2005-11-24
ES2231667T3 (es) 2005-05-16
ATE283856T1 (de) 2004-12-15
DE60202134D1 (en) 2005-01-05
EP1368352A1 (en) 2003-12-10
CA2439528A1 (en) 2002-09-26
JP2004523585A (ja) 2004-08-05
BR0208154A (pt) 2004-03-02
MXPA03005937A (es) 2003-09-10
EP1368352B1 (en) 2004-12-01
WO2002074774A1 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
GB0106661D0 (en) Pharmaceutically active compounds
GB9823103D0 (en) Pharmaceutically active compounds
CA2287552A1 (en) Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
BR0004779A (pt) Compostos farmaceuticamente ativos
AU5995699A (en) Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
AP2002002455A0 (en) 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
CA2322900A1 (en) 2-(hetero)aryl-substituted purin-6-ones as phosphodiesterase inhibitors
MXPA03006310A (es) Compuestos farmaceuticamente activos.
MY148652A (en) New crystalline form of a triazolo(4,5-d)pyrimidine compound
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
IL158667A0 (en) Imidazo [1,2-a] pyridine derivatives for the prophylaxis and treatment of herpes viral infections
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
CA2413510A1 (en) Condensed pyrazindione derivatives
WO2002079203A8 (en) Imidazo-triazine derivatives as pde 5 inhibitors
AP2002002462A0 (en) Pharmaceutically active compounds.
EP1241170A3 (en) Pyrazolopyrimidine derivatives
WO2001015684A3 (en) Antimycotic drug
ECSP003706A (es) Compuestos farmaceuticamente activos
AU4485101A (en) Antiviral therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)